Viridian Therapeutics, Inc.\DE (VRDN) Return on Capital Employed (2014 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Return on Capital Employed of 48.67% for Q1 2026, up 178.0% year-over-year from 17.51% in Q1 2025, and up 10.58% quarter-over-quarter from 54.43% in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Return on Capital Employed (2014 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Return on Capital Employed history runs 13 years deep, the most recent figure standing at 48.67% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 178.0% year-over-year to 48.67%; the TTM figure through Mar 2026 stood at 48.67% (up 178.0% YoY), while the FY2025 annual figure was 48.44%, up 416.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 48.67%, up from 54.43% in the prior quarter.
- The five-year high for Return on Capital Employed was 33.2% in Q4 2022, with the low at 73.23% in Q3 2023.
- The 5-year median for Return on Capital Employed is 48.67% (2026), against an average of 52.42%.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed surged 6419 bps in 2022, then sank 3324 bps in 2023.
- Viridian Therapeutics, Inc.\DE's Return on Capital Employed stood at 33.2% in 2022, then plunged by 100 bps to 66.44% in 2023, then jumped by 37 bps to 42.16% in 2024, then slipped by 29 bps to 54.43% in 2025, then increased by 11 bps to 48.67% in 2026.
- Business Quant data shows VRDN's Return on Capital Employed at 48.67% in Q1 2026, 54.43% in Q4 2025, and 62.02% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | -46.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -46.08% |
| Mar 31, 2026 | -48.67% |
| Dec 31, 2025 | -54.43% |
| Sep 30, 2025 | -62.02% |
| Jun 30, 2025 | -65.30% |
| Mar 31, 2025 | -50.45% |
| Dec 31, 2024 | -42.16% |
| Sep 30, 2024 | -44.40% |
| Jun 30, 2024 | -43.90% |
| Mar 31, 2024 | -44.52% |
| Dec 31, 2023 | -66.44% |
| Sep 30, 2023 | -73.23% |
| Jun 30, 2023 | -61.87% |
| Mar 31, 2023 | -47.44% |
| Dec 31, 2022 | -33.20% |
| Sep 30, 2022 | -40.83% |
| Jun 30, 2022 | -63.62% |
| Mar 31, 2022 | -48.65% |
| Dec 31, 2021 | -40.10% |
| Sep 30, 2021 | -90.91% |